ArticleJournal of veterinary internal medicine2026
Association between PCV and degree of azotemia with serum hepcidin concentration in cats with chronic kidney disease.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundChronic kidney disease (CKD) in cats is common and often leads to anemia. Hepcidin, an acute-phase protein and regulator of iron metabolism, is a potential biomarker for CKD-associated anemia. HYPOTHESIS/
objectivesTo validate a hepcidin-25 ELISA for cats. To compare serum hepcidin concentrations in cats with CKD grouped by PCV, and explore associations between hepcidin and other clinicopathological variables. ANIMALS: One hundred client-owned cats with naturally occurring CKD.
methodsRetrospective cross-sectional study. Cats with azotemic CKD were categorized by PCV: anemic (<28%), low-normal (LN-PCV, 28%-33%), or normal PCV (N-PCV, 35%-43%). LN-PCV and N-PCV groups were matched for plasma creatinine concentration, age, bodyweight, body and muscle condition scores. Associations between serum hepcidin concentrations, serum amyloid A (SAA), and clinicopathological variables were evaluated. Multiple regression analysis identified independent associations with hepcidin.
resultsThe hepcidin-25 ELISA demonstrated acceptable precision, reproducibility, and specificity. Hepcidin was higher in anemic cats (median [range], 3.1 ng/mL [1.17-6.58]) compared to LN-PCV (2.21 ng/mL [1.24-6.94]) and N-PCV cats (2.29 ng/mL [1.41-7.72) (P = .007), with no difference between the latter two groups (P > .99). Hepcidin was weakly positively correlated with plasma creatinine (r = 0.265, P = .008) and plasma phosphate (r = 0.214, P = .034); no significant correlations were observed between hepcidin and PCV, SAA, or other clinicopathological variables. Plasma creatinine alone was associated with hepcidin in multivariable analysis, explaining <15% of the variance. CONCLUSIONS AND CLINICAL IMPORTANCE: Serum hepcidin concentration is higher in cats with CKD once anemia is established. Its association with plasma creatinine suggests kidney dysfunction influences its excretion, although additional factors not assessed in this study likely contribute.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.